BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% on Better-Than-Expected Earnings

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were up 10.7% during trading on Friday following a stronger than expected earnings report. The stock traded as high as $8.62 and last traded at $8.7490. Approximately 2,803,466 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 4,386,014 shares. The stock had previously closed at $7.90.

The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. The company had revenue of $163.28 million during the quarter, compared to analysts’ expectations of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 69.22% and a net margin of 30.16%.The business’s revenue was up 209.1% on a year-over-year basis. During the same period last year, the firm posted ($0.13) earnings per share.

Key Stories Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings sharply beat expectations — GAAP EPS of $1.12 vs. consensus ~$0.07 and quarter revenue above estimates, signaling much stronger profitability and accelerating top‑line growth; investors likely reacted to the surprise beat. Zacks: Q4 Earnings Beat
• Positive Sentiment: Full‑year 2025 results showed strong ORLADEYO performance (net revenue $601.8M, +38% y/y), supporting ongoing revenue momentum and improving free‑cash expectations. GlobeNewsWire: Full‑Year 2025 Results
• Positive Sentiment: Astria acquisition and accompanying guidance boost BioCryst’s HAE franchise and pipeline positioning, which can drive longer‑term revenue expansion and investor confidence in commercial scale. TipRanks: Astria Acquisition
• Positive Sentiment: Analyst sentiment is constructive — consensus rating described as “Moderate Buy,” which can support further upside as coverage and buy‑side interest increases. American Banking News: Analyst Rating
• Neutral Sentiment: Management’s earnings presentation and call provide detail on profitability drivers and product outlook — useful for due diligence but not an immediate directional surprise. Seeking Alpha: Earnings Presentation
• Neutral Sentiment: Market commentary is debating valuation after the recent rebound — some see upside while others question whether the run is already priced in. Yahoo Finance: Valuation Discussion
• Neutral Sentiment: Reported short‑interest data in feeds appears inconsistent (zeros/NaN) and shouldn’t be relied on; no clear short squeeze signal from the published figures.
• Negative Sentiment: Despite the beats, the company still reported a negative net margin and negative ROE; analysts expect negative FY EPS (~‑0.36), so investors should watch sustainability of profits and future guidance. MarketBeat: Earnings Summary

Analysts Set New Price Targets

Several brokerages have recently weighed in on BCRX. Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Citizens Jmp decreased their price target on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, November 5th. Royal Bank Of Canada lowered their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. HC Wainwright boosted their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, Evercore began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.64.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 91,004 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the sale, the insider directly owned 416,152 shares in the company, valued at approximately $2,954,679.20. The trade was a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 183,453 shares of company stock worth $1,330,965 over the last quarter. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in BCRX. Invesco Ltd. raised its holdings in BioCryst Pharmaceuticals by 40.8% in the 4th quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock valued at $10,568,000 after acquiring an additional 392,521 shares in the last quarter. Mackenzie Financial Corp raised its stake in BioCryst Pharmaceuticals by 16.6% in the fourth quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock valued at $1,152,000 after purchasing an additional 21,411 shares in the last quarter. NewEdge Advisors LLC acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $390,000. XTX Topco Ltd bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $133,000. Finally, Vestal Point Capital LP acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $17,550,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

The firm’s fifty day simple moving average is $7.14 and its 200 day simple moving average is $7.39. The stock has a market capitalization of $1.84 billion, a P/E ratio of 7.29 and a beta of 0.83.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.